Retinal expression, regulation and functional bioactivity of prostacyclin-stimulating factor

Journal of Clinical Investigation

Volumn 106, Issue 4, 2000, Pages 541-550

  Hata, Yasuaki ^a   Clermont, Allen ^a   Yamauchi, Teruaki ^a   Pierce, Eric A ^b   Suzuma, Izumi ^a   Kagokawa, Hiroyuki ^a   Yoshikawa, Hiroshi ^c   Robinson, Gregory S ^d   Ishibashi, Tatsuro ^c   Hashimoto, Toshihiko ^c   Umeda, Fumio ^c   Bursell, Sven E ^a   Aillo, Lloyd Paul ^a,e  

^a JOSLIN DIABETES CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c KYUSHU UNIVERSITY   (Japan)

^d HYBRIDON INC   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; BASIC FIBROBLAST GROWTH FACTOR; PROSTACYCLIN; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CATTLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; GENE EXPRESSION; GENE EXPRESSION REGULATION; HEMODYNAMICS; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RAT; RETINA BLOOD FLOW; RETINA NEOVASCULARIZATION;

EID: 0033863072     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI8338     Document Type: Article

References (59)

1. Bursell, S.E., et al. 1996. Retinal blood flow changes in patients with insulin-dependent diabetes mellitus and no diabetic retinopathy. Am. J. Physiol. 270:R61-R70.
2. Clermont, A.C., Aiello, L.P., Mori, F., Aiello, L.M., and Bursell, S.E. 1997. Vascular endothelial growth factor and severity of nonproliferative diabetic retinopathy mediate retinal hemodynamics in vivo: a potential role for vascular endothelial growth factor in the progression of nonproliferative diabetic retinopathy. Am. J. Ophthalmol. 124:433-446.
3. Konno, S., et al. 1996 Retinal blood flow changes in type I diabetes. A long-term follow-up study. Invest. Ophthalmol. Vis. Sci. 37:1140-1148.
4. Yamauchi, T., et al. 1994. Purification and molecular cloning of prostacyclin-stimulating factor from serum-free conditioned medium of human diploid fibroblast cells. Biochem. J. 303:591-598.
5. Mizushima, S., et al. 1996. Isolation and characterization of the human chromosomal gene for prostacyclin-stimulating factor. J. Biochem. (Tokyo). 120:929-933.
6. Ono, Y., et al. 1998. Reduced expression of a novel peptide, prostacyclin-stimulating factor, in the kidneys of streptozotocin-induced diabetic rats. J. Diabetes Complications. 12:252-258.
7. Sekiguchi, N., et al. 1997. Immunohistochemical study of prostacyclin-stimulating factor (PSF) in the diabetic and atherosclerotic human coronary artery. Diabetes. 46:1627-1632.
8. Umeda, F., et al. 1996. Prostacyclin-stimulating factor, novel protein, and diabetic angiopathy. Diabetes. 45(Suppl. 3):S111-S113.
9. Ono, Y., et al. 1998. Effect of high glucose concentrations on prostacyclin-stimulating factor mRNA expression in cultured aortic smooth muscle cells. Diabetologia. 41:134-140.
10. Masakado, M., et al. 1995. Immunohistochemical localization of a novel peptide, prostacyclin-stimulating factor (PSF), in human tissues. Thromb. Haemost. 74:1407-1410.
11. Ono, Y., et al. 1994. Expression of prostacyclin-stimulating factor, a novel protein, in tissues of Wistar rats and in cultured cells. Biochem. Biophys. Res. Commun. 202:1490-1496.
12. Umeda, F., et al. 1998. Increased mRNA expression of a novel prostacyclin-stimulating factor in human colon cancer. J. Gastroenterol. 33:213-217.
13. Weksler, B.B., Ley, C.W., and Jaffe, E.A. 1978. Stimulation of endothelial cell prostacyclin production by thrombin, trypsin, and the ionophore A 23187. J. Clin. Invest. 62:923-930.
14. Coughlin, S.R., Moskowitz, M.A., Zetter, B.R., Antoniades, H.N., and Levine, L. 1980. Platelet-dependent stimulation of prostacyclin synthesis by platelet-derived growth factor. Nature. 288:600-602.
15. Rossi, V., Breviario, F., Ghezzi, P., Dejana, E., and Mantovani, A. 1985. Prostacyclin synthesis induced in vascular cells by interleukin-1. Science. 229:174-176.
16. Kawakami, M., et al. 1986. Cachectin/TNF as well as interleukin-1 induces prostacyclin synthesis in cultured vascular endothelial cells. Biochem. Biophys. Res. Commun. 141:482-487.
17. Ristimaki, A., Ylikorkala, O., Perheentupa, J., and Viinikka, L. 1988. Epidermal growth factor stimulates prostacyclin production by cultured human vascular endothelial cells. Thromb. Haemost. 59:248-250.
18. Ristimaki, A. 1989. Transforming growth factor alpha stimulates prostacyclin production by cultured human vascular endothelial cells more potently than epidermal growth factor. Biochem. Biophys. Res. Commun. 160:1100-1105.
19. Hardy, P., et al. 1998. A major role for prostacyclin in nitric oxide-induced ocular vasorelaxation in the piglet. Circ. Res. 83:721-729.
20. Dodge, A.B., Hechtman, H.B., and Shepro, D. 1991. Microvascular endothelial-derived autacoids regulate pericyte contractility. Cell Motil. Cytoskeleton. 18:180-188.
21. Murohara, T., et al. 1998. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation. 97:99-107.
22. Wheeler-Jones, C., et al. 1997. Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42/p44 mitogen-activated protein kinase. FEBS Lett. 420:28-32.
23. Rymaszewski, Z., et al. 1992. Human retinal vascular cells differ from umbilical cells in synthetic functions and their response to glucose. Proc. Soc. Exp. Biol. Med. 199:183-191.
24. Hata, Y., Duh, E., Zhang, K., Robinson, G.S., and Aiello, L.P. 1998. Transcription factors Sp1 and Sp3 alter vascular endothelial growth factor receptor expression through a novel recognition sequence. J. Biol. Chem. 273:19294-19303.
25. Chomczynski, P., and Sacchi, N. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156-159.
26. Sharma, K., and Ziyadeh, F.N. 1994. Renal hypertrophy is associated with upregulation of TGF-beta 1 gene expression in diabetic BB rat and NOD mouse. Am. J. Physiol. 267:F1094-F1101.
27. Aiello, L.P., Robinson, G.S., Lin, Y.W., Nishio, Y., and King, G.L. 1994. Identification of multiple genes in bovine retinal pericytes altered by exposure to elevated levels of glucose by using mRNA differential display. Proc. Natl. Acad. Sci. USA. 91:6231-6235.
28. Smith, L.E., et al. 1994. Oxygen-induced retinopathy in the mouse. Invest. Ophthalmol. Vis. Sci. 35:101-111.
29. Aiello, L.P., et al. 1995. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl. Acad. Sci. USA. 92:10457-10461.
30. Shiba, T., et al. 1993. Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation. Am. J. Physiol. 265:E783-E793.
31. Takagi, C., et al. 1995. Reversal of abnormal retinal hemodynamics in diabetic rats by acarbose, an alpha-glucosidase inhibitor. Proc. Natl. Acad. Sci. USA. 92:10457-10461.
32. Clermont, A.C., et al. 1994. Normalization of retinal blood flow in diabetic rats with primary intervention using insulin pumps. Invest. Ophthalmol. Vis. Sci. 35:981-990.
33. Takagi, C., et al. 1996. Endothelin-1 action via endothelin receptors is a primary mechanism modulating retinal circulatory response to hyperoxia. Invest. Ophthalmol. Vis. Sci. 37:2099-2109.
34. Takagi, C., et al. 1996. Regulation of retinal hemodynamics in diabetic rats by increased expression and action of endothelin-1. Invest. Ophthalmol. Vis. Sci. 37:2504-2518.
35. Ishii, H., et al. 1996. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science. 272:728-731.
36. Koyama, T., et al. 1990. Retinal circulation times in quantitative fluorescein angiography. Graefes. Arch. Clin. Exp. Ophthalmol. 228:442-446.
37. Riva, C.E., Feke, G.T., and Ben-Sira, I. 1978. Fluorescein dye-dilution technique and retinal circulation. Am. J. Physiol. 234:H315-H322.
38. Bulpitt, C.J., and Dollery, C.T. 1971. Estimation of retinal blood flow by measurement of the mean circulation time. Cardiovasc. Res. 5:406-412.
39. Aiello, L.P., et al. 1997. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes. 46:1473-1480.
40. Higashi, S., Clermont, A.C., Dhir, V., and Bursell, S.E. 1998. Reversibility of retinal flow abnormalities is disease-duration dependent in diabetic rats. Diabetes. 47:653-659.
41. Grunwald, J.E., Riva, C.E., Sinclair, S.H., Brucker, A.J., and Petrig, B.L. 1986. Laser Doppler velocimetry study of retinal circulation in diabetes mellitus. Arch. Ophthalmol. 104:991-996.
42. Yoshida, A., et al. 1983. Retinal blood flow alterations during progression of diabetic retinopathy. Arch. Ophthalmol. 101:225-227.
43. Barst, R.J., Maislin, G., and Fishman, A.P. 1999. Vasodilator therapy for primary pulmonary hypertension in children. Circulation. 99:1197-1208.
44. Cogan, D.G., and Kuwabara, T. 1963. Capillary shunts in the pathogenesis of diabetic retinopathy. Diabetes. 12:293-300.
45. Cogan, D.G., Toussaint, D., and Kuwabara, T. 1961. Retinal vascular patterns. IV. Diabetic retinopathy. Arch. Ophthalmol. 66:366-378.
46. Toussaint, D., Cogan, D.G., and Kuwabara, T. 1999. Extravascular lesions of diabetic retinopathy. Arch. Ophthalmol. 67:42-47.
47. Aiello, L.P., et al. 1994. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 331:1480-1487.
48. Adamis, A.P., et al. 1994. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am. J. Ophthalmol. 118:445-450.
49. Behzadian, M.A., Wang, X.L., Shabrawey, M., and Caldwell, R.B. 1998. Effects of hypoxia on glial cell expression of angiogenesis-regulating factors VEGF and TGF-beta. Glia. 24:216-225.
50. Hueber, A., Wiedemann, P., Esser, P., and Heimann, K. 1996. Basic fibroblast growth factor mRNA, bFGF peptide and FGF receptor in epiretinal membranes of intraocular proliferative disorders (PVR and PDR). Int. Ophthalmol. 20:345-350.
51. Seghezzi, G., et al. 1998. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J. Cell Biol. 141:1659-1673.
52. Hata, Y., Rook, S.L., and Aiello, L.P. 1999. Basic fibroblast growth factor induces expression of VEGF receptor KDR through a protein kinase C and p44/p42 mitogen-activated protein kinase-dependent pathway. Diabetes. 48:1145-1155.
53. Xia, P., et al. 1994. Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes. 43:1122-1129.
54. Yamagishi, S., Kobayashi, K., and Yamamoto, H. 1993. Vascular pericytes not only regulate growth, but also preserve prostacyclin-producing ability and protect against lipid peroxide-induced injury of co-cultured endothelial cells. Biochem. Biophys. Res. Commun. 190:418-425.
55. Hudes, G.R., Li, W.Y., Rockey, J.H., and White, P. 1988. Prostacyclin is the major prostaglandin synthesized by bovine retinal capillary pericytes in culture. Invest. Ophthalmol. Vis. Sci. 29:1511-1516.
56. Sato, Y., and Rifkin, D.B. 1989. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-beta 1-like molecule by plasmin during co-culture. J. Cell Biol. 109:309-315.
57. Ishibashi, T., Inomata, H., Sakamoto, T., and Ryan, S.J. 1995. Pericytes of newly formed vessels in experimental subretinal neovascularization. Arch. Ophthalmol. 113:227-231.
58. Pierce, E.A., Avery, R.L., Foley, E.D., Aiello, L.P., and Smith, L.E. 1995. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc. Natl. Acad. Sci. USA. 92:905-909.
59. Pierce, E.A., Foley, E.D., and Smith, L.E. 1996. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity [erratum 1997, 115:427]. Arch. Ophthalmol. 114:1219-1228.